GYRE - Gyre Therapeutics, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
8.12 0.75 (9.24%)	---	---	---	0.34 (4.19%)	0.57 (6.87%)	---	0.34 (4.19%)

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: 0.0
Diluted EPS:: 0.0
Basic P/E:
Diluted P/E:
RSI(14) 1m:: 62.1
VWAP:: 8.87
RVol:: 1.6615

Events

Period	Kind	Movement	Occurred At
10m	Price decrease 10m	8.65 -0.28 (-3.14%)	Oct 15 10:19
1m	Price decrease 1m	8.7 -0.11 (-1.25%)	Oct 15 10:15
1m	Price increase 1m	8.94 +0.1 (+1.15%)	Oct 15 09:55
10m	Price increase 10m	8.94 +0.36 (+4.2%)	Oct 15 09:55
Day	Price increase day	8.94 +0.82 (+10.1%)	Oct 15 09:55